UFSP2 constitutes a targetable vulnerability via deUFMylation-dependent activation of AKT oncogenic signaling
Wang et al. show that UFMylation restrains AKT kinase activity, while its loss promotes colorectal tumor growth and resistance to the FDA-approved AKT inhibitor capivasertib.